 |
|
Acetazolamide-Induced Thrombocytopenia
Arch Ophthalmol. 2004;122:1543-1544.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Acetazolamide (Diamox; Duramed Pharmaceuticals Inc, Cincinnati, Ohio) is a carbonic anhydrase inhibitor commonly used in ophthalmology to reduce intraocular pressure and to treat some forms of macular edema. Acetazolamide-associated thrombocytopenia was previously described as part of aplastic anemia or other organ involvement; however, evidence that the drug may also cause accelerated platelet destruction has never been provided.1-2 Herein we report an acetazolamide-induced pure thrombocytopenia with the highest level of evidence for a causal relationship of the drug to thrombocytopenia.
Report of a Case
A 67-year-old man who had been receiving metformin for 20 years because of type 2 diabetes mellitus was admitted to our department for cataract surgery. The day after the surgery, intraocular pressure was elevated and 2 daily 250-mg tablets of acetazolamide were prescribed. As the intraocular pressure normalized on day 3, acetazolamide was stopped. A routine blood cell count with examination of the blood smear disclosed an unexpected and isolated thrombocytopenia . . . [Full Text of this Article]
Comment
Laurent Kodjikian, MD, PhD;
Brigitte Durand, PhD;
Carole Burillon, MD;
Frédéric Rouberol, MD;
Jean-Daniel Grange, MD;
Philippe Renaudier, MD
Correspondence: Dr Renaudier, Department of Hematology, Croix-Rousse Hospital, 103, grande rue de la Croix-Rousse, Lyon 69004, France (philippe.renaudier@chu-lyon.fr).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
|
